Trial Profile
A longitudinal, single site study to evaluate the long term efficacy natalizumab therapy in patients with multiple sclerosis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 May 2017
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Biogen
- 28 Apr 2017 Results (n= 135) of preliminary analysis comparing baseline characteristics of patients treated with natalizumab versus healthy control, presented at the 69th Annual Meeting of the American Academy of Neurology
- 24 Feb 2016 New trial record
- 10 Oct 2015 Interim analysis (n=35) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.